Compare DNN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | VKTX |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 1998 | 2014 |
| Metric | DNN | VKTX |
|---|---|---|
| Price | $3.31 | $29.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $6.50 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 42.3M | 2.2M |
| Earning Date | 03-10-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $237.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $18.92 |
| 52 Week High | $4.43 | $43.15 |
| Indicator | DNN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 39.28 |
| Support Level | $2.56 | $25.67 |
| Resistance Level | $3.36 | $30.15 |
| Average True Range (ATR) | 0.22 | 1.91 |
| MACD | -0.05 | -0.43 |
| Stochastic Oscillator | 4.07 | 1.05 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.